當前位置:廣州健侖生物科技有限公司>>食品安全檢測>>尼古丁快速檢測試劑盒>> 尼古丁唾液快速檢測試紙
尼古丁唾液快速檢測試紙
廣州健侖生物科技?有限公司
本司長期供應尼古?。商鎸帲z測試劑盒,其主要品牌包括美國NovaBios、廣州健侖、廣州創侖等進口產品,國產產品,試劑盒的實驗方法是膠體金方法。
我司還提供其它進口或國產試劑盒:登革熱、瘧疾、流感、A鏈球菌、合胞病毒、腮病毒、乙腦、寨卡、黃熱病、基孔肯雅熱、克錐蟲病、違禁品濫用、肺炎球菌、軍團菌等試劑盒以及日本生研細菌分型診斷血清、德國SiFin診斷血清、丹麥SSI診斷血清等產品。
歡迎咨詢
歡迎咨詢
【包裝規格】
1人份/袋,40人份/盒
【預期用途】
尼古丁(Nicotine)是煙草中的主要生物堿,是導致吸煙成癮的物質動因,也是評價人體攝入煙草煙霧的常用指標。但因為尼古丁半衰期短,無法作為標志物檢測,其代謝物可替寧因為半衰期長作為吸煙和戒煙的標志物。
本品采用競爭抑制法和膠體金免疫層析技術,用于快速定性檢測人體唾液中的可替寧,適用于評價煙草煙霧攝入的初步篩查。
【主要組成成份】
【檢驗方法】
尼古丁唾液快速檢測試紙
通過重復上述的篩選與擴增循環,那些與靶物質不結合或與靶物質親和力較低的DNA或RNA分子被洗掉,而與靶物質有強親和力的DNA或RNA分子被分離出來,且純度隨SELEX過程的進行而增高,從pmol到nmol,有的甚至到μmol,zui后占據庫的大多數 (>90%左右),隨著寡核苷酸庫的逐漸富集對靶標的親和性也增加。一般經過6-15輪的循環就可以獲得特異性的適配體。
適配體(Aptamer)的概念在1990年*被提出,通常是利用體外篩選技術——指數富集的配體系統進化技術 (systematic evolution of ligands by exponential enrichment,SELEX) 從特定的寡核苷酸庫中篩選出對目標分子有特異性相互作用的寡核苷酸 (DNA或RNA),能與相應的配體進行高親和力和強特異性的結合。與傳統的抗體相比,適配體具有以下特點和優勢:
(1) 對目標靶分子具有與抗體相當甚至更高的親和性和特異性;
(2) 可以大量、快速的在體外合成,制備方法更為簡單快捷;
(3) 可以針對不同種類的目標分子進行篩選,包括生物毒性分子以及只具有半抗原性的分子,拓寬了其應用范圍;
(4) 不受免疫原性和免疫條件限制,變性與復性可逆;
(5) 穩定性優于抗體,利于儲存;
(6) 可定量檢測。
基于適配體的上述優良特性,其在疾病檢測、藥物研發、臨床治療、生物醫學等多個領域都有著良好的應用前景。在檢測抗原方面,適配體已逐漸取代抗體,并在一定程度上彌補了抗體在診斷應用中的不足。不僅如此,適配體還可以作為拮抗劑,特異地與疾病發生過程中起重要作用的靶物質的表位相結合,有封阻這類靶分子的功能,從而達到緩解和治療的目的。因此,理論上適配體可被用于診斷及治療因有害基因的表達而引起的疾病,如細菌感染等。
結核菌素是結核桿菌的菌體成分,其中純蛋白衍生物(purified protein derivative,PPD)是由塞伯爾(Seibert)首先制備的。
想了解更多的韓國SD產品及服務請掃描下方二維碼:我司還提供其它進口或國產試劑盒:登革熱、瘧疾、流感、A鏈球菌、合胞病毒、腮病毒、乙腦、寨卡、黃熱病、基孔肯雅熱、克錐蟲病、違禁品濫用、肺炎球菌、軍團菌等試劑盒以及日本生研細菌分型診斷血清、德國SiFin診斷血清、丹麥SSI診斷血清等產品。
二維碼掃一掃
【公司名稱】 廣州健侖生物科技有限公司
【】 楊永漢
【】
【騰訊 】
【公司地址】 廣州清華科技園創新基地番禺石樓鎮創啟路63號二期2幢101-3室
【企業文化宣傳】
By repeating the above screening and amplification cycles, those DNA or RNA molecules that do not bind to the target substance or have a lower affinity for the target substance are washed off, and the DNA or RNA molecules that have a strong affinity for the target substance are separated, and the purity With the progress of SELEX process increased, from pmol to nmol, some even to μmol, and finally occupy the majority of the library (> 90%), with the gradual enrichment of the oligonucleotide library on the target affinity increase. Generally 6-15 rounds of cycles can be obtained after the specific aptamers.
The concept of aptamers was first proposed in 1990, and is usually based on the systematic evolution of ligands by exponential enrichment (SELEX) using in vitro screening techniques from specific oligonucleotides In the library, oligonucleotides (DNA or RNA) specific for the target molecule are screened for high-affinity and strong-specificity binding to the corresponding ligands. Compared with traditional antibodies, aptamers have the following features and advantages:
(1) have an affinity or specificity comparable to or even higher for the target molecule of interest;
(2) can be large, rapid synthesis in vitro, the preparation method is more simple and quick;
(3) Screening for different kinds of target molecules, including biotoxic molecules and hapten only, broaden the scope of its application;
(4) Immunogenicity and immunological conditions are not restricted, and the degeneration and refolding are reversible.
(5) the stability is better than the antibody, conducive to storage;
(6) can be quantitative testing.
Based on the above excellent characteristics of aptamers, it has good application prospects in many fields such as disease detection, drug development, clinical treatment and biomedicine. In the detection of antigen, aptamers have been gradually replaced by antibodies, and to some extent make up for the lack of antibodies in diagnostic applications. Not only that, aptamers can also act as antagonists that specifically bind to epitopes of target substances that play an important role in the pathogenesis of disease, blocking the function of such target molecules, and thereby achieving the goal of remission and treatment. Therefore, in theory, aptamers can be used to diagnose and treat diseases caused by the expression of deleterious genes, such as bacterial infections.
Tuberculin is a bacterial component of Mycobacterium tuberculosis, of which purified protein derivative (PPD) was first prepared by Seibert.
請輸入賬號
請輸入密碼
請輸驗證碼
以上信息由企業自行提供,信息內容的真實性、準確性和合法性由相關企業負責,智慧城市網對此不承擔任何保證責任。
溫馨提示:為規避購買風險,建議您在購買產品前務必確認供應商資質及產品質量。